Slynd is a drug owned by Exeltis Usa Inc. It is protected by 15 US drug patents filed from 2019 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 28, 2031. Details of Slynd's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9603860 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | Active |
| US10603281 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | Active |
| US11413249 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US11951213 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US11478487 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US11439598 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US11504334 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US11123299 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US10987364 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US11291632 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US11291633 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US11351122 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US10179140 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | Active |
| US12090231 | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | Active |
| US10849857 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | Active |
FDA has granted several exclusivities to Slynd. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Slynd, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Slynd.
Exclusivity Information
Slynd holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Slynd's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2022 |
Several oppositions have been filed on Slynd's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Slynd's generic, the next section provides detailed information on ongoing and past EP oppositions related to Slynd patents.
Slynd's Oppositions Filed in EPO
Slynd has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 12, 2022, by Adalvo Ltd.. This opposition was filed on patent number EP19209672A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19209672A | Oct, 2022 | Luigi, Rumi | Granted and Under Opposition |
| EP19209672A | Oct, 2022 | Adalvo Ltd. | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Slynd is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Slynd's family patents as well as insights into ongoing legal events on those patents.
Slynd's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Slynd's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 28, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Slynd Generic API suppliers:
Drospirenone is the generic name for the brand Slynd. 1 company has already filed for the generic of Slynd. Check out the entire list of companies who have already received approval for Slynd's generic
How can I launch a generic of Slynd before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Slynd's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Slynd's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Slynd -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 4 mg | 07 Jan, 2022 | 1 | 28 Jun, 2031 |
Alternative Brands for Slynd
Slynd which is used for preventing pregnancy in females of reproductive age., has several other brand drugs in the same treatment category and using the same active ingredient (Drospirenone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Exeltis Usa Inc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Drospirenone. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Drospirenone, Slynd's active ingredient. Check the complete list of approved generic manufacturers for Slynd
About Slynd
Slynd is a drug owned by Exeltis Usa Inc. It is used for preventing pregnancy in females of reproductive age. Slynd uses Drospirenone as an active ingredient. Slynd was launched by Exeltis Usa Inc in 2019.
Can you believe Slynd received compensation for the extended wait time during the regulatory approval process?
A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent. The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.
Approval Date:
Slynd was approved by FDA for market use on 23 May, 2019.
Active Ingredient:
Slynd uses Drospirenone as the active ingredient. Check out other Drugs and Companies using Drospirenone ingredient
Treatment:
Slynd is used for preventing pregnancy in females of reproductive age.
Dosage:
Slynd is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 4MG | TABLET | Prescription | ORAL |